BCIQ Profiles

Company Profile Report

Icosavax’s self-assembling vaccine platform

With $51M in series A funds, Icosavax aims to show its de novo protein VLPs make potent vaccines for RSV

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its first program through Phase Ib testing.

Virus-like particles (VLPs) -- viral proteins that self-assemble into inert nanoparticles that resemble viral capsids -- have found clinical and commercial success in vaccines including HPV vaccine Gardasil from Merck

Read the full 702 word article

How to gain access

Continue reading with a
two-week free trial.